United European Gastroenterology Journal最新文献

筛选
英文 中文
External validation of models to predict hepatocellular carcinoma in Hepatitis C Virus cured F3-F4 patients. 丙型肝炎病毒治愈 F3-F4 患者肝细胞癌预测模型的外部验证。
IF 5.8 2区 医学
United European Gastroenterology Journal Pub Date : 2024-09-01 Epub Date: 2024-05-08 DOI: 10.1002/ueg2.12571
Ângela Carvalho-Gomes, Tsveta Vladi Valcheva Valcheva, Iván Sahuco, Enrique Vidal, Laura Martínez-Arenas, Carmen Vinaixa, Victoria Aguilera, Sónia García García, Marina Berenguer
{"title":"External validation of models to predict hepatocellular carcinoma in Hepatitis C Virus cured F3-F4 patients.","authors":"Ângela Carvalho-Gomes, Tsveta Vladi Valcheva Valcheva, Iván Sahuco, Enrique Vidal, Laura Martínez-Arenas, Carmen Vinaixa, Victoria Aguilera, Sónia García García, Marina Berenguer","doi":"10.1002/ueg2.12571","DOIUrl":"10.1002/ueg2.12571","url":null,"abstract":"<p><strong>Background & aims: </strong>Several hepatocellular carcinoma (HCC) risk-models have been developed to individualise patient surveillance following sustained viral response (SVR) in Hepatitis C Virus patients. Validation of these models in different cohorts is an important step to incorporate a more personalised risk assessment in clinical practice. We aimed at applying these models to stratify the risk in our patients and potentially determine cost-saving associated with individualised HCC risk-stratification screening strategy.</p><p><strong>Methods: </strong>Patients with baseline F3-4 fibrosis treated with new oral direct-acting antivirals who had reached a SVR were regularly followed as part of the HCC surveillance strategy. Six models were applied: Pons, aMAP, Ioannou, HCC risk, Alonso and Semmler. Validation of the models was performed based on sensitivity and the proportion of patients labelled as \"high risk\".</p><p><strong>Results: </strong>After excluding 557 with less than 3 fibrosis, 12 without SVR, 18 with a follow up (FU) <1 year, 17 transplant recipients, 16 lost to FU and 31 with HCC at time of antiviral therapy, our cohort consisted of 349 F3-4 SVR patients. Twenty-three patients (6.6%) developed HCC after a median FU of 5.12 years. The sensitivity of the different models varied between 0.17 (Semmler7noalcohol) and 1 (Alonso A and aMAP). The lowest proportion of high-risk patients corresponded to the Semmler-noalcohol model (5%). Sixty-three and 90% of the Alonso A and aMAP patients, respectively were labelled as high risk. The most reliable HCC risk-model applied to our cohort to predict HCC development is the Alonso model (based on fibrosis stage assessed by liver stiffness measurements or Fibrosis-4 index (FIB-4) at baseline and after 1 year, and albumin levels at 1 year) with a-100% sensitivity in detecting HCC among those at high risk and 63% labelled as high risk. The application of the model would have saved the cost of 1290 ultrasound no longer being performed in the 37% low-risk group.</p><p><strong>Conclusion: </strong>In our cohort, the Alonso A model allows the most reliable reduction in HCC screening resulting in safely stopping life-long monitoring in about a third of F3-F4 patients achieving SVR with DAAs.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140892768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse events with endoscopic ultrasound-guided gastroenterostomy for gastric outlet obstruction-A systematic review and meta-analysis. 内镜超声引导下胃肠造口术治疗胃出口梗阻的不良事件--系统回顾和荟萃分析。
IF 5.8 2区 医学
United European Gastroenterology Journal Pub Date : 2024-09-01 Epub Date: 2024-05-15 DOI: 10.1002/ueg2.12576
Suprabhat Giri, Sidharth Harindranath, Babu P Mohan, Vaneet Jearth, Jijo Varghese, Marko Kozyk, Aditya Kale, Sridhar Sundaram
{"title":"Adverse events with endoscopic ultrasound-guided gastroenterostomy for gastric outlet obstruction-A systematic review and meta-analysis.","authors":"Suprabhat Giri, Sidharth Harindranath, Babu P Mohan, Vaneet Jearth, Jijo Varghese, Marko Kozyk, Aditya Kale, Sridhar Sundaram","doi":"10.1002/ueg2.12576","DOIUrl":"10.1002/ueg2.12576","url":null,"abstract":"<p><strong>Background: </strong>The technical and clinical effectiveness of endoscopic ultrasonography (EUS)-guided gastroenterostomy (GE) has been reported by several meta-analyses, but few of them have addressed the adverse events (AE). The goal of the current meta-analysis was to analyze the AEs associated with various types of EUS-GE.</p><p><strong>Methods: </strong>All relevant studies reporting the AEs with EUS-GE were searched from 2000 to 31st March 2023 in MEDLINE, Embase, and Scopus. The event rates were pooled using a random effects model.</p><p><strong>Results: </strong>A total of 36 studies (n = 1846) were included in the meta-analysis. The present meta-analysis reports a pooled technical success rate of 96.9% (95.9-98.0; I<sup>2</sup> = 29.3%) with a pooled clinical success rate of 90.6% (88.5-92.7; I<sup>2</sup> = 60.9%). The pooled incidence of overall AEs with EUS-GE was 13.0% (10.3-15.7; I<sup>2</sup> = 69.7%), with the commonest being maldeployment of the stent, seen in 4.6% (3.2-6.0; I<sup>2</sup> = 50.6%). The pooled incidences of serious AE and procedure-related mortality were 1.2% (0.7-1.8; I<sup>2</sup> = 1.9%) and 0.3% (0.0-0.7; I<sup>2</sup> = 0.0%), respectively. Subgroup analysis of studies using only the free-hand technique showed a significantly lower overall AE and maldeployment but not serious AE and other individual AEs. The pooled incidences of delayed stent migration and stent occlusion were 0.5% (0.0-1.1; I<sup>2</sup> = 0.0%) and 0.8% (0.2-1.3; I<sup>2</sup> = 0.0%), respectively.</p><p><strong>Conclusion: </strong>Despite a technical and clinical success rate of >90%, AEs are seen in around one-seventh of the cases of EUS-GE, maldeployment being the commonest. However, the pooled incidence of serious AE and mortality remains low, which is reassuring.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140923064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Seeing the whole picture: Inflammatory bowel disease complications and extraintestinal manifestations on cross-sectional imaging. 纵观全局:横断面成像上的炎症性肠病并发症和肠外表现。
IF 5.8 2区 医学
United European Gastroenterology Journal Pub Date : 2024-09-01 Epub Date: 2024-07-05 DOI: 10.1002/ueg2.12619
Maria Manuela Estevinho, Nurulamin M Noor
{"title":"Seeing the whole picture: Inflammatory bowel disease complications and extraintestinal manifestations on cross-sectional imaging.","authors":"Maria Manuela Estevinho, Nurulamin M Noor","doi":"10.1002/ueg2.12619","DOIUrl":"10.1002/ueg2.12619","url":null,"abstract":"","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141545246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can endoscopists judge a book by its cover when it comes to Barrett cancer? 谈到巴雷特癌,内窥镜医生能以貌取人吗?
IF 5.8 2区 医学
United European Gastroenterology Journal Pub Date : 2024-09-01 Epub Date: 2024-07-15 DOI: 10.1002/ueg2.12638
V Bos, R E Pouw
{"title":"Can endoscopists judge a book by its cover when it comes to Barrett cancer?","authors":"V Bos, R E Pouw","doi":"10.1002/ueg2.12638","DOIUrl":"10.1002/ueg2.12638","url":null,"abstract":"","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is it time to revise criteria and treatment of type 2 autoimmune pancreatitis? 是时候修订 2 型自身免疫性胰腺炎的标准和治疗方法了吗?
IF 5.8 2区 医学
United European Gastroenterology Journal Pub Date : 2024-09-01 Epub Date: 2024-07-20 DOI: 10.1002/ueg2.12637
Diane Lorenzo, Vinciane Rebours
{"title":"Is it time to revise criteria and treatment of type 2 autoimmune pancreatitis?","authors":"Diane Lorenzo, Vinciane Rebours","doi":"10.1002/ueg2.12637","DOIUrl":"10.1002/ueg2.12637","url":null,"abstract":"","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141731432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of long-course chemoradiotherapy on the myenteric plexus, neuromuscular functions and responses to prokinetic drugs in the human rectum. 长期化放疗对人体直肠肠肌丛、神经肌肉功能和促动力药物反应的影响。
IF 5.8 2区 医学
United European Gastroenterology Journal Pub Date : 2024-08-31 DOI: 10.1002/ueg2.12653
Victor W S Kung, John Broad, Raj Makwana, Alexandra Palmer, Nicholas Baidoo, Sarah Epton, Shezan Elahi, Joanne Chin-Aleong, Mohamed Thaha, Charles H Knowles, Gareth J Sanger
{"title":"The impact of long-course chemoradiotherapy on the myenteric plexus, neuromuscular functions and responses to prokinetic drugs in the human rectum.","authors":"Victor W S Kung, John Broad, Raj Makwana, Alexandra Palmer, Nicholas Baidoo, Sarah Epton, Shezan Elahi, Joanne Chin-Aleong, Mohamed Thaha, Charles H Knowles, Gareth J Sanger","doi":"10.1002/ueg2.12653","DOIUrl":"https://doi.org/10.1002/ueg2.12653","url":null,"abstract":"<p><strong>Background & aims: </strong>The long-term effects of chemoradiotherapy on human rectum are poorly understood. The aims were to investigate changes in inflammatory status, myenteric neuron numbers/phenotype, neuromuscular functions and prokinetic drug efficacy.</p><p><strong>Methods: </strong>Macroscopically normal proximal-to-mid rectum was obtained from 21 patients undergoing surgery for bowel cancer, 98 days (range: 63-350) after concurrent capecitabine and pelvic radiotherapy, and 19 patients without chemoradiotherapy. Inflammatory status was measured by H&E, CD45 staining and qPCR. Myenteric neurons were examined by immunohistochemistry. Neuromuscular functions and drug efficacy were studied using exogenous agents and electrical field stimulation (EFS) to activate intrinsic nerves.</p><p><strong>Results: </strong>Inflammation was not detected. Numbers of myenteric ganglia/neurons were unchanged (11.7 ± 2.4 vs. 10.3 ± 2.2 neurons/mm myenteric plexus with/without chemoradiotherapy) as were the numbers of cholinergic/nitrergic neurons. EFS stimulated cholinergic and nitrergic neurons so the contractile response of the muscle was the sum of both but dominated by cholinergic (causing contraction) or less often, nitrergic activity (relaxation), followed, after termination of EFS, by neuronally mediated contraction. Inhibition of nitric oxide synthase (by L-NAME 300 μM) more clearly defined EFS-evoked contractions. The 5-HT<sub>4</sub> agonist prucalopride 10 μM and the cholinesterase inhibitor donepezil 1 µM, respectively increased and greatly increased the composite contractile response to EFS (measured as 'area-under-the curve') and the contractions isolated by L-NAME (respectively, by 22 ± 14% and 334 ± 87%; n = 11/8). After chemoradiotherapy, nitrergic-mediated muscle relaxations occurred more often during EFS (in 29.8 ± 6.1% preparations vs. 12.6 ± 5.1% without chemoradiotherapy, n = 21/18). With L-NAME, the ability of prucalopride to facilitate EFS-evoked contraction was lost and that of donepezil approximately halved (contractions increased by 132 ± 36%; n = 8).</p><p><strong>Conclusions: </strong>Several months after chemoradiotherapy, the rectum was not inflamed and myenteric neuron numbers/phenotype unchanged. However, nitrergic activity was increased relative to cholinergic activity, and prokinetic-like drug activity was lost or greatly reduced. Thus, chemoradiotherapy causes long-term changes in neuromuscular functions and markedly reduces the efficacy of drugs for treating constipation.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammatory bowel disease genomics, transcriptomics, proteomics and metagenomics meet artificial intelligence. 炎症性肠病基因组学、转录组学、蛋白质组学和元基因组学与人工智能的结合。
IF 5.8 2区 医学
United European Gastroenterology Journal Pub Date : 2024-08-31 DOI: 10.1002/ueg2.12655
Anna Lucia Cannarozzi, Anna Latiano, Luca Massimino, Fabrizio Bossa, Francesco Giuliani, Matteo Riva, Federica Ungaro, Maria Guerra, Anna Laura Di Brina, Giuseppe Biscaglia, Francesca Tavano, Sonia Carparelli, Gionata Fiorino, Silvio Danese, Francesco Perri, Orazio Palmieri
{"title":"Inflammatory bowel disease genomics, transcriptomics, proteomics and metagenomics meet artificial intelligence.","authors":"Anna Lucia Cannarozzi, Anna Latiano, Luca Massimino, Fabrizio Bossa, Francesco Giuliani, Matteo Riva, Federica Ungaro, Maria Guerra, Anna Laura Di Brina, Giuseppe Biscaglia, Francesca Tavano, Sonia Carparelli, Gionata Fiorino, Silvio Danese, Francesco Perri, Orazio Palmieri","doi":"10.1002/ueg2.12655","DOIUrl":"https://doi.org/10.1002/ueg2.12655","url":null,"abstract":"<p><p>Various extrinsic and intrinsic factors such as drug exposures, antibiotic treatments, smoking, lifestyle, genetics, immune responses, and the gut microbiome characterize ulcerative colitis and Crohn's disease, collectively called inflammatory bowel disease (IBD). All these factors contribute to the complexity and heterogeneity of the disease etiology and pathogenesis leading to major challenges for the scientific community in improving management, medical treatments, genetic risk, and exposome impact. Understanding the interaction(s) among these factors and their effects on the immune system in IBD patients has prompted advances in multi-omics research, the development of new tools as part of system biology, and more recently, artificial intelligence (AI) approaches. These innovative approaches, supported by the availability of big data and large volumes of digital medical datasets, hold promise in better understanding the natural histories, predictors of disease development, severity, complications and treatment outcomes in complex diseases, providing decision support to doctors, and promising to bring us closer to the realization of the \"precision medicine\" paradigm. This review aims to provide an overview of current IBD omics based on both individual (genomics, transcriptomics, proteomics, metagenomics) and multi-omics levels, highlighting how AI can facilitate the integration of heterogeneous data to summarize our current understanding of the disease and to identify current gaps in knowledge to inform upcoming research in this field.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient preferences for the diagnosis of coeliac disease: A discrete choice experiment. 患者对乳糜泻诊断的偏好:离散选择实验
IF 5.8 2区 医学
United European Gastroenterology Journal Pub Date : 2024-08-27 DOI: 10.1002/ueg2.12651
Mohamed G Shiha, Nyantara Wickramasekera, Suneil A Raju, Hugo A Penny, David S Sanders
{"title":"Patient preferences for the diagnosis of coeliac disease: A discrete choice experiment.","authors":"Mohamed G Shiha, Nyantara Wickramasekera, Suneil A Raju, Hugo A Penny, David S Sanders","doi":"10.1002/ueg2.12651","DOIUrl":"https://doi.org/10.1002/ueg2.12651","url":null,"abstract":"<p><strong>Background: </strong>There is potential for a paradigm shift from a biopsy-to a serology-based diagnosis of coeliac disease in selected adult patients. However, it remains unknown if this approach would be acceptable to patients. We aimed to explore patients' preferences regarding the no-biopsy approach for coeliac disease diagnosis.</p><p><strong>Methods: </strong>We developed a discrete choice experiment survey containing 12 different scenarios with two possible alternatives (endoscopy & biopsy or serology) to estimate patient preferences. The scenarios were based on 5 attributes: risk of false positive results, risk of missed diagnosis, waiting time to start treatment, risk of complications, discomfort, or pain. Patient preferences and the relative importance of the attributes were estimated using a mixed logit model.</p><p><strong>Results: </strong>In total, 385 people (70.6% female, 98.2% white) across the four nations of the United Kingdom completed the survey. Respondents preferred a serology-based diagnosis over endoscopy and duodenal biopsies (59% vs. 41%, β coefficient 1.54, p < 0.001). Diagnostic test accuracy (p < 0.001), shorter waiting time to start treatment (p < 0.001), and discomfort levels during the procedure (p < 0.001) were the most important attributes to respondents. The risk of complications, including perforation and bleeding, did not significantly influence respondents' choices. Respondents with previous endoscopy experience were more willing to undergo endoscopy compared with those who never had one.</p><p><strong>Conclusion: </strong>The no-biopsy approach to diagnosing coeliac disease is acceptable and preferred by patients over endoscopy and biopsy. Our findings highlight the importance of patient-centred care and shared decision-making in guiding diagnostic strategies for optimal patient outcomes.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune profiling of premalignant lesions in patients with Peutz-Jeghers syndrome. 佩兹-杰格尔斯综合征患者癌前病变的免疫图谱分析。
IF 5.8 2区 医学
United European Gastroenterology Journal Pub Date : 2024-08-22 DOI: 10.1002/ueg2.12650
Zhongyue Liu, Boda Wu, Xiaoliu Shi, Junfeng Zhou, Hui Huang, Zhihong Li, Mei Yang
{"title":"Immune profiling of premalignant lesions in patients with Peutz-Jeghers syndrome.","authors":"Zhongyue Liu, Boda Wu, Xiaoliu Shi, Junfeng Zhou, Hui Huang, Zhihong Li, Mei Yang","doi":"10.1002/ueg2.12650","DOIUrl":"https://doi.org/10.1002/ueg2.12650","url":null,"abstract":"<p><strong>Background: </strong>Peutz-Jeghers syndrome (PJS), is a rare autosomal dominant hereditary disease characterized by an elevated risk of various cancers. Serine/Threonine Kinase 11 (STK11) gene is a major tumor suppressor crucial for immune evasion with and beyond tumorigenic cells. It has garnered increasing attention in the realm of oncology treatment, particularly in the context of immunotherapy development.</p><p><strong>Objective: </strong>This study aimed to assess the suitability of polyps obtained from individuals with PJS, resulting from germline STK11 deficiency, for immunotherapy. Additionally, we seek to identify potential shared mechanisms related to immune evasion between PJS polyps and cancers. To achieve this, we examined PJS polyps alongside familial adenomatous polyposis (FAP) and sporadic polyps.</p><p><strong>Methods: </strong>Polyps were compared among themselves and with either the paracancerous tissues or colon cancers. Pathological and gene expression profiling approaches were employed to characterize infiltrating immune cells and assess the expression of immune checkpoint genes.</p><p><strong>Results: </strong>Our findings revealed that PJS polyps exhibited a closer resemblance to cancer tissues than other polyps in terms of their immune microenvironment. Notably, PJS polyps displayed heightened expression of the immune checkpoint gene CD80 and an accumulation of myeloid cells, particularly myeloid-derived suppressor cells (MDSCs).</p><p><strong>Conclusion: </strong>The findings suggest an immunobiological foundation for the increased cancer susceptibility in PJS patients, paving the way for potential immune therapy applications in this population. Furthermore, utilizing PJS as a model may facilitate the exploration of immune evasion mechanisms, benefiting both PJS and cancer patients.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries. 在LEGACy联盟中,与标准三联疗法相比,四联疗法对幽门螺杆菌感染的根除率更高。一项在欧洲和拉丁美洲国家开展的多中心观察研究。
IF 5.8 2区 医学
United European Gastroenterology Journal Pub Date : 2024-08-01 DOI: 10.1002/ueg2.12605
Patricio Medel-Jara, Diego Reyes Placencia, Eduardo Fuentes-López, Oscar Corsi, Gonzalo Latorre, Rosario Antón, Elena Jiménez, Ana Miralles-Marco, Carmelo Caballero, Hugo Boggino, Daniel Cantero, Rita Barros, João Santos-Antunes, Marc Díez, Luis A Quiñones, Erick Riquelme, Antonio Rollán, Leslie C Cerpa, Ivania Valdés, Olga P Nyssen, Leticia Moreira, Javier P Gisbert, M Constanza Camargo, Nayeli Ortiz-Olvera, Alberto M Leon-Takahashi, Erika Ruiz-Garcia, Edith A Fernández-Figueroa, Marcelo Garrido, Gareth I Owen, Andrés Cervantes, Tania Fleitas, Arnoldo Riquelme
{"title":"Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries.","authors":"Patricio Medel-Jara, Diego Reyes Placencia, Eduardo Fuentes-López, Oscar Corsi, Gonzalo Latorre, Rosario Antón, Elena Jiménez, Ana Miralles-Marco, Carmelo Caballero, Hugo Boggino, Daniel Cantero, Rita Barros, João Santos-Antunes, Marc Díez, Luis A Quiñones, Erick Riquelme, Antonio Rollán, Leslie C Cerpa, Ivania Valdés, Olga P Nyssen, Leticia Moreira, Javier P Gisbert, M Constanza Camargo, Nayeli Ortiz-Olvera, Alberto M Leon-Takahashi, Erika Ruiz-Garcia, Edith A Fernández-Figueroa, Marcelo Garrido, Gareth I Owen, Andrés Cervantes, Tania Fleitas, Arnoldo Riquelme","doi":"10.1002/ueg2.12605","DOIUrl":"https://doi.org/10.1002/ueg2.12605","url":null,"abstract":"<p><strong>Introduction: </strong>Gastric cancer (GC) is one of the most lethal malignancies worldwide. Helicobacter pylori is the primary cause of GC; therefore, its eradication reduces the risk of developing this neoplasia. There is extensive evidence regarding quadruple therapy with relevance to the European population. However, in Latin America, data are scarce. Furthermore, there is limited information about the eradication rates achieved by antibiotic schemes in European and Latin American populations.</p><p><strong>Objective: </strong>To compare the effectiveness of standard triple therapy (STT), quadruple concomitant therapy (QCT), and bismuth quadruple therapy (QBT) in six centers in Europe and Latin America.</p><p><strong>Methods: </strong>A retrospective study was carried out based on the LEGACy registry from 2017 to 2022. Data from adult patients recruited in Portugal, Spain, Chile, Mexico, and Paraguay with confirmed H. pylori infection who received eradication therapy and confirmatory tests at least 1 month apart were included. Treatment success by each scheme was compared using a mixed multilevel Poisson regression, adjusting for patient sex and age, together with country-specific variables, including prevalence of H. pylori antibiotic resistance (clarithromycin, metronidazole, and amoxicillin), and CYP2C19 polymorphisms.</p><p><strong>Results: </strong>772 patients were incorporated (64.64% females; mean age of 52.93 years). The total H. pylori eradication rates were 75.20% (255/339) with STT, 88.70% (159/178) with QCT, and 91.30% (191/209) with QBT. Both quadruple therapies (QCT-QBT) showed significantly higher eradication rates compared with STT, with an adjusted incidence risk ratio (IRR) of 1.25 (p: <0.05); and 1.24 (p: <0.05), respectively. The antibiotic-resistance prevalence by country, but not the prevalence of CYP2C19 polymorphism, showed a statistically significant impact on eradication success.</p><p><strong>Conclusions: </strong>Both QCT and QBT are superior to STT for H. pylori eradication when adjusted for country-specific antibiotic resistance and CYP2C19 polymorphism in a sample of individuals residing in five countries within two continents.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信